Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: A case control study

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Torres Poveda, K ^a   Burguete Garcia A I ^a   Bahena Roman M ^a   Mendez Martinez R ^b   Zurita Diaz M A ^a   Lopez Estrada G ^c   Delgado Romero, K ^d   Peralta Zaragoza, O ^a   Bermudez Morales V H ^a   Cantu D ^b   Garcia Carranca A ^b,e   Madrid Marina, V ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c Private Health Center for Gynecology   (Mexico)

^d Center for Women's Health   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cervical neoplasm; Cytokines; Genetic susceptibility profile; Promoter polymorphisms; Serum levels

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; TUMOR MARKER;

ADAPTIVE IMMUNITY; ADULT; AGE DISTRIBUTION; ALLELIC DISCRIMINATION; ALLELIC LOAD; ARTICLE; BLOOD SAMPLING; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENETIC ANALYSIS; GENETIC PARAMETERS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEXICAN; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TH2 CELL; TH3 CELL; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; ALLELE; CANCER STAGING; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TH1 CELL; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; ALLELES; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TH1 CELLS; TH2 CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 84969972260     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2364-4     Document Type: Article

References (59)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675-86.
2. INEGI. Estadísticas de mortalidad. Cubos dinámicos y CONAPO 2012. Proyecciones de la población de México 2012-2050. 2012.
3. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011;20:287-96.
4. Conesa-Zamora P. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. Gynecol Oncol. 2013;131(2):480-8.
5. Bermúdez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V. Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest. 2008;26(10):1037-43.
6. Torres-Poveda K, Burguete-García AI, Cruz M, Martínez-Nava GA, Bahena-Román M, Ortíz-Flores E, et al. The SNP at -592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development. Infect Agent Cancer. 2012;7(1):32-40.
7. Basavaraju U, Shebl FM, Palmer AJ, Berry S, Hold GL, El-Omar EM, et al. Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland. Eur J Cancer Prev. 2015;24(4):296-304.
8. Zhang X, Zhang L, Tian C, Yang L, Wang Z. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. BJOG. 2014;121(6):664-74.
9. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1-10.
10. Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009;100(7):1191-7.
11. Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer. 2000;88(5):698-701.
12. Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006;19(3):481-91.
13. Díaz-Benítez CE, Navarro-Fuentes KR, Flores-Sosa JA, Juárez-Díaz J, Uribe-Salas FJ, Román-Basaure E, et al. CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. J Clin Immunol. 2009;29(4):532-44.
14. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 2011;4(3):361-75.
15. Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O, et al. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol. 2014;5(4):753-63.
16. Shamran HA, Hamza SJ, Yaseen NY, Al-Juboory AA, Taub DD, Price RL, et al. Impact of single nucleotide polymorphism in IL-4, IL-4R genes and systemic concentration of IL-4 on the incidence of glioma in Iraqi patients. Int J Med Sci. 2014;11(11):1147-53.
17. Tsai MH, Chen WC, Tsai CH, Hang LW, Tsai FJ. Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal. 2005;19(3):93-8.
18. Zheng Z, Li X, Li Z, Ma XC. IL-4 -590C/T polymorphism and susceptibility to liver disease: a meta-analysis and meta-regression. DNA Cell Biol. 2013;32(8):443-50.
19. Lim WY, Chen Y, Ali SM, Chuah KL, Eng P, Leong SS, et al. Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis. 2011;32(4):522-9.
20. Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population-A candidate gene approach. Int J Cancer. 2009;125(8):1851-8.
21. Veerapaneni P, Kirma N, Nair HB, Hammes LS, Hall KL, Tekmal RR. Elevated aromatase expression correlates with cervical carcinoma progression. Gynecol Oncol. 2009;114:496-500.
22. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001;82:49-56.
23. Shi TY, Zhu ML, He J, Wang MY, Li QX, Zhou XY, et al. Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet. 2013;132:301-12.
24. Grimm C, Watrowski R, Baumühlner K, Natter C, Tong D, Wolf A, et al. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol. 2011;121(3):537-41.
25. Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem. 2004;50(11):2136-40.
26. Kong SY, Lee HL, Eom HS, Park WS, Yun T, Kim HJ, et al. Reference intervals for circulating angiogenic cytokines. Clin Chem Lab Med. 2008;46(4):545-50.
27. Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E, et al. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci. 2005;37:111-3.
28. Ni J, Ye Y, Teng F, Wu Q. Interleukin 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2013;23(1):126-33.
29. Steinke JW, Barekzi E, Hagman J, Borish L. Functional Analysis of -571 IL-10 promoter polymorphism reveals a repressor element controlled by Sp1. J Immunol. 2004;173:3215-22.
30. Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94(6):792-4.
31. Ding Q, Shi Y, Fan B, Fan Z, Ding L, Li F, et al. The Interleukin-10 Promoter Polymorphism rs1800872 (-592C.A), Contributes to Cancer Susceptibility: Meta-Analysis of 16 785 Cases and 19 713 Controls. PLoS ONE. 2013;8(2):e57246.
32. Singh H, Jain M, Sachan R, Mittal B. Association of TNFA (-308G > A) and IL-10 (-819C > T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer. 2009;19(7):1190-4.
33. Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10-819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS. 2013;17(4):200-14.
34. Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer. 2012;12:102.
35. Wang J, Ding Q, Shi Y, Cao Q, Qin C, Zhu J, et al. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis. 2012;27(3):305-12.
36. Rees L, Wood N, Gillespie K, Lai K, Gaston K, Mathieson P. The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci. 2002;59(3):560-9.
37. Matsumoto K, Oki A, Satoh T, Okada S, Minaguchi T, Onuki M, et al. Interleukin-10-1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 2010;40:1113-6.
38. Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi E, et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet. 2002;29:237-40.
39. Barbisan G, Pérez LO, Contreras A, Golijow CD. TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumor Biol. 2012;33:1549-56.
40. Shah R, Hurley CK, Posch PE. A molecular mechanism for the differential regulation of TGF-beta1 expression due to the common SNP -509C-T (c. -1347C > T). Hum Genet. 2006;120(4):461-9.
41. Singh H, Jain M, Mittal B. Role of TGF-beta1 (-509C > T) promoter polymorphism in susceptibility to cervical cancer. Oncol Res. 2009;18(1):41-5.
42. Ramos-Flores C, Romero-Gutiérrez T, Delgado-Enciso I, Maldonado GE, Plascencia VM, Vazquez-Vuelvas OF, et al. Polymorphisms in the genes related to angiogenesis are associated with uterine cervical cancer. Int J Gynecol Cancer. 2013;23(7):1198-204.
43. Liu L, Yang X, Chen X, Kan T, Shen Y, Chen Z, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2683-8.
44. Ding B, Fu S, Wang M, Yue C, Wang W, Zhou D, et al. Tumor necrosis factor α -308 G > A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2012;22(2):213-9.
45. Pan F, Tian J, Ji CS, He YF, Han XH, Wang Y, et al. Association of TNF-α-308 and -238 Polymorphisms with Risk of Cervical Cancer: A Meta-analysis. Asian Pac J Cancer Prev. 2012;13(11):5777-83.
46. Jin Y. Association of Single Nucleotide Polymorphisms in Tumor Necrosis Factor-Alpha with Cervical Cancer Susceptibility. Cell Biochem Biophys. 2015;71(1):77-84.
47. Zhang H-L, Zhang YJ. A systemic assessment of the association between tumor necrosis factor alpha 308G/A polymorphism and risk of cervical cancer. Tumor Biol. 2013;34(3):1659-65.
48. Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308- promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:14853.
49. Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South african women with cervical cancer and control women. BMC Cancer. 2006;6:24.
50. Ivansson EL, Magnusson JJ, Magnusson PK, Erlich HA, Gyllensten UB. MHC loci affecting cervical cancer risk: distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2. Genes Immun. 2008;9(7):613-23.
51. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48(8):1218-24.
52. Baena A, Leung JY, Sullivan AD, Landires I, Vasquez-Luna N, Quiñones-Berrocal J, et al. TNF-alpha promoter single nucleotide polymorphisms are markers of human ancestry. Genes Immun. 2002;3:482-7.
53. Kim K, Cho SK, Sestak A, Namjou B, Kang C, Bae SC. Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis. 2010;69(6):1247-50.
54. Li CJ, Dai Y, Fu YJ, Tian JM, Li JL, Lu HJ, et al. Correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis. Tumour Biol. 2014;35(7):6867-77.
55. Song SH, Lee JK, Lee NW, Saw HS, Kang JS, Lee KW. Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol. 2008;108(3):543-8.
56. Lages EL, Belo AV, Andrade SP, Rocha MÂ, de Freitas GF, Lamaita RM, et al. Analysis of systemic inflammatory response in the carcinogenic process of uterine cervical neoplasia. Biomed Pharmacother. 2011;65(7):496-9.
57. - cervical lesions. J Immunotoxicol. 2012;9(2):168-72.
58. Chechlinska M, Kowalska M, Kaminska J. Cytokines as potential tumour markers. Expert Opin Med Diagn. 2008;2(6):691-711.
59. Arany I, Grattendick KG, Tyring SK. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5'-segment of the upstream regulatory region (URR). Antiviral Res. 2002;55(2):331-9.